Catalent

New Jersey
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Caution
Medium Risk

Summary:

By complying with the HRC’s controversial demands, Catalent increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also prioritizes DEI criteria in employee recruitment and vendor selection. Catalent forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Its CEO signed the CEO Action for Diversity & Inclusion pledge, which includes a commitment to promote DEI through bias education training in the workplace. Catalent is a bronze sponsor of Out & Equal. The company opposed various state and local legislation intended to protect parental rights, girls’ sports, bathroom facilities, and gendered spaces. For these reasons, Catalent receives a Medium Risk rating.

Generate Reports
Clear
Toast